On November 9, HENGRUI PHARMA fell 3.07% in Regular Trading, with the stock trading at HK$50.55 and turnover of HK$65.38 million.
The clearest recent catalyst is the company’s disclosure that the first 12-month lock-up period under its 2025 A-share employee stock ownership plan expired on November 7, making 4.7137 million shares eligible for unlocking after company-level and individual-level performance targets were met.
The unlocked tranche represents 0.07% of total share capital and involves 1,127 participants. The broader plan had received 13.5111 million shares via non-trading transfer in November last year. Recent company-specific developments were otherwise constructive, including clinical trial approvals for two oncology drugs and FDA acceptance of a resubmitted BLA for camrelizumab plus apatinib, but recent position changes by institutions also showed mixed flows, including JPMorgan’s long position ratio falling to 9.47%.
(The above content is based on publicly available market information, generated by a program or algorithm, and is intended solely as a stock movement alert. It does not constitute investment advice or a basis for trading decisions.)
Comments